cobimetinib

Cobimetinib is an orally administered, potent, and highly selective small molecule inhibitor of mitogen‑activated protein kinase kinase (MEK) 1 and MEK2. It is classified as a kinase inhibitor and functions by blocking the action of abnormal proteins in the RAS/RAF/MEK/ERK signaling pathway that drive cancer cell proliferation. Cobimetinib is primarily indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. It is also approved as a single agent for treating histiocytic neoplasms, a group of rare blood cancers characterized by overproduction and accumulation of certain white blood cells. The drug was developed by Genentech/Roche and received its initial FDA approval in November 2015[2][3][8].

Brand names

Cotellic

Other names

cobimetinibGDC-0973GDC0973GDC 0973XL518XL-518XL 518RG7420RG-7420RG 7420RO5514041RO-5514041RO 5514041